5 May 2016 - People with advanced liposarcomas in Europe may now be able to receive Halaven (eribulin mesylate), the first and only single agent therapy to show a significant survival advantage in this type of soft tissue sarcoma.

The European Commission has approved a variation to the terms of the Marketing Authorisation of eribulin mesylate for the treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

In January 2016 the FDA approved eribulin mesylate for the treatment of people in the US with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. License was granted in Japan to extend the indication of eribulin mesylate to treat patients with soft tissue sarcomas in February 2016.

For more details, go to: http://www.prnewswire.co.uk/news-releases/european-commission-approves-halaven-eribulin-for-treatment-of-advanced-liposarcoma-in-europe-578184871.html